General

Home > Cartherics News > General

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.

The company, in […]

2022-09-30T16:02:08+10:00September 30th, 2022|
Read More

3 Cheers for a Cartherics Board Member

Bryan Williams ranked among the world’s most prominent scientists

By Leigh Dayton, 16 June 2022

Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.

In the recently released edition its […]

2022-06-16T09:19:26+10:00June 16th, 2022|
Read More

She’s an Adventurer, Advocate, Author and a Cancer Survivor

Now Heather Hawkins is a member of the Cartherics Board

By Leigh Dayton  9 June 2022

It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.

“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]

2022-06-09T14:44:04+10:00June 9th, 2022|
Read More

Presentation at the Locust Walk Stem Cell Tx Conference

Dr Ian Nisbet Chief Operating Officer

Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited […]

2022-04-08T11:41:15+10:00April 8th, 2022|
Read More

7th Innate Killer Summit 2022, Dr Nicholas Boyd Presenting

7th Innate Killer Summit (San Diego, California)

Cartherics Chief Development Officer, Dr Nicholas Boyd

The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment. From 30 March-1 April 2022 Pacific Daylight Time (PDT) industry experts will meet in San Diego, California to discuss […]

2022-04-01T18:33:22+11:00March 25th, 2022|
Read More

The 4th Allogeneic Cell Therapies Summit is the leading industry-dedicated meeting that considers pre-clinical development, translation, manufacturing, supply and storage of allogeneic cell therapies to improve the accessibility and efficacy of patient care worldwide.

400+ experts from pharma, biotech and leading academia are expected to attend in Boston, USA […]

2022-03-04T14:28:58+11:00March 4th, 2022|
Read More

Presentation at the Next Generation CAR-TCR Summit (London, UK)

Presentation at the Next Generation CAR-TCR Summit (London, UK)

Cartherics Chief Development Officer, Dr Nicholas Boyd

CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing […]

2022-03-08T18:59:41+11:00February 23rd, 2022|
Read More

Presentation: Multi-Functional Cell Therapies Summit

Chief Development Officer, Dr Nicholas Boyd

Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.

On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]

2022-01-27T16:58:33+11:00January 27th, 2022|
Read More
Copyright ©     |   Cartherics Pty ltd
Go to Top